Pharmaceuticals News and Research

RSS

Wilson Therapeutics supports BIG WOW event to increase awareness of Wilson's Disease

Wilson Therapeutics AB, a privately-held biopharmaceutical company, today announced its sponsorship of the first annual Big Walk on Wilson's (BIG WOW). The event will take place on September 19, 2015 in sixteen cities across North America to increase awareness of Wilson's Disease and raise funds for the Wilson Disease Association.

17 Jun 2015

Allergan agrees to acquire KYTHERA Biopharmaceuticals for $2.1 billion

Allergan plc, a leading global pharmaceutical company, and KYTHERA Biopharmaceuticals, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of novel prescription products for the aesthetic medicine market, today announced that they have entered into a definitive agreement under which Allergan has agreed to acquire KYTHERA in a cash and equity transaction valued at $75 per KYTHERA share, or approximately $2.1 billion.

17 Jun 2015

RPCI receives NCI grant to continue research program on photodynamic therapy for head and neck cancers

Roswell Park Cancer Institute has received continuation of a prestigious program project grant from the National Cancer Institute for research through the Roswell Park Photodynamic Therapy Center.

17 Jun 2015

Rapamycin drug reduces obesity, preserves lean body mass in older rats

Aging can cause many changes to the body, including obesity and a loss of lean mass. Now, a group of University of Florida Health researchers has discovered that an existing drug reduces body fat and appetite in older rats, which has intriguing implications for aging humans.

17 Jun 2015

Iowa's advanced driving simulator to help assess newly developed artificial lens for cataract patients

A miniature version of the University of Iowa's advanced driving simulator will participate in a clinical trial later this year to assess a patient's driving ability after cataract surgery.

17 Jun 2015

DCRI announces new study to better understand lipid management

At a time when lipid management in the United States is undergoing transition in response to new guideline recommendations and expanding lipid-lowering therapy options, the Duke Clinical Research Institute (DCRI) today announced a new study to better understand contemporary lipid management as well as the beliefs and attitudes of patient and providers regarding cholesterol, cardiovascular risk assessment, and options for lipid treatments.

17 Jun 2015

Atopix raises additional development capital to investigate OC459 for treatment of asthma

Atopix Therapeutics Limited, a UK biopharmaceutical company developing a novel class of medicines to treat atopic dermatitis and severe asthma, today announced that it has raised additional development capital to advance its lead product OC459 for the treatment of asthma.

17 Jun 2015

CytomX closes $70 million Series D financing round

CytomX, a biotechnology company developing Probody™ therapeutics for the treatment of cancer, today announced the closing of a $70 million Series D financing round. The financing was led by Fidelity Management & Research Company with participation from Casdin Capital, Cormorant Asset Management, Deerfield Management, Perceptive Advisors, Redmile Group, Tekla Healthcare Investors and Tekla Life Sciences Investors, Venrock Healthcare Capital Partners, Wellington Management Company and additional undisclosed investors.

17 Jun 2015

CQDM, OCE grant $1.5M to speed up drug discovery and development in Quebec-Ontario Life Sciences Corridor

CQDM and Ontario Centres of Excellence will fund five highly innovative and unconventional game-changing research and development projects to accelerate drug discovery in the Quebec-Ontario Life Sciences Corridor. Partners are granting $1.5M to Quebec-based and, for the first time, Ontario-based researchers thanks to the partnership with OCE through CQDM's 2014 Explore Program, one of CQDM's flagship programs focusing on early concept validation of cutting-edge technologies that address the most crucial needs in drug discovery and development.

17 Jun 2015

Phase I study: Idarucizumab reverses anticoagulant effect of dabigatran in healthy volunteers

Boehringer Ingelheim Pharmaceuticals, Inc. today announced that The Lancet published results from a phase I study investigating the effects of idarucizumab, an investigational agent, in reversing the anticoagulant effect of dabigatran in healthy volunteers. The data demonstrate that complete reversal was achieved following administration of idarucizumab.

17 Jun 2015

Key prostaglandin metabolic enzyme shows promise as drug target for tissue regeneration

A new study co-led by Hsin-Hsiung Tai, professor of pharmaceutical sciences at the University of Kentucky, suggests that a key prostaglandin (PG) metabolic enzyme shows promise as a drug target to help tissue regeneration and repair, particularly after bone marrow transplantation and tissue injuries.

16 Jun 2015

Apexigen initiates APX005M Phase 1 clinical trial in adults with solid tumors

Apexigen, Inc., a biopharmaceutical company discovering and developing innovative antibody drugs for the treatment of cancer and other life-threatening diseases, announced today the initiation of a Phase 1 clinical trial of APX005M, the company's lead proprietary anticancer program.

16 Jun 2015

Omeros signs exclusive license agreement with Fagron affiliates for commercialization of OMS103

Omeros Corporation, a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for both large-market as well as orphan indications, today announced that it has entered into an exclusive license agreement with affiliates of Fagron NV for the commercialization of OMS103, Omeros' product for arthroscopic surgery.

16 Jun 2015

BiondVax invited to present at EDUFULVAC-NIAID workshop on immunoassay standardization for universal flu vaccines

BiondVax Pharmaceuticals Ltd., a clinical stage biopharmaceutical company focused on developing and commercializing immunomodulation therapies for infectious diseases,today announced that it has been invited to present in a workshop organized by EDUFULVAC, (EDUcate inFLUenza VACcine) a corresponding European Consortium coordinated by the European Vaccine Initiative (Germany) and NIAID (the National Instituteof Allergy and Infectious Diseases, a National Institute of Health branch) in the United States.

16 Jun 2015

Pulmatrix announces new inhaled anti-infective therapy to treat CF-associated fungal infections

Pulmatrix, Inc., a clinical stage biopharmaceutical company developing innovative inhaled therapies for serious pulmonary diseases, today announced a new drug candidate, PUR1900, an inhaled anti-infective to treat fungal infections associated with cystic fibrosis (CF).

16 Jun 2015

Althea obtains European GMP certificate from HPRA for commercial aseptic filling and testing

Ajinomoto Althea, Inc., a leading provider of biopharmaceutical contract development and manufacturing services announced today that it has officially received its European GMP certificate from the Health Products Regulatory Authority for commercial aseptic filling and testing.

16 Jun 2015

Pulmatrix completes previously announced merger and closes $10 million in private placement

Pulmatrix, Inc., previously known as Ruthigen, Inc., today announced the completion of its previously announced merger, effective June 15, 2015, and the closing of a private placement generating aggregate gross proceeds of $10.0 million. Participants in the private placement included pre-merger investors in Pulmatrix such as funds affiliated with 5AM Ventures, ARCH Venture Partners and Polaris Partners, as well as funds affiliated with Altitude Life Science Ventures.

16 Jun 2015

Pulmatrix signs ex-U.S. development agreement with Mylan for bronchodilator therapy

Pulmatrix, a clinical stage biopharmaceutical company developing innovative inhaled therapies for serious pulmonary diseases, today announced that it has entered into an ex-U.S. development agreement with Mylan N.V., one of the world's leading global pharmaceutical companies.

16 Jun 2015

West Pharmaceutical Services hosts groundbreaking ceremony for new manufacturing facility in Ireland

West Pharmaceutical Services, Inc., a global leader in innovative packaging components and drug delivery systems, hosted a groundbreaking ceremony in Waterford, Ireland today to mark the start of construction for the company's new pharmaceutical component manufacturing facility. Attended by Cllr James Tobin, Mayor of Waterford City and County; Cllr Lola O'Sullivan, Mayor of Waterford Metropolitan District; and other local officials, the event celebrated West's continued investment in Ireland and commitment to the local Waterford community.

16 Jun 2015

Pharmacists play vital role in improving health of patients with Type 2 diabetes

Over the past nine years, Scot H. Simpson, professor in the faculty of Pharmacy and Pharmaceutical Sciences at the University of Alberta, has been studying the role of pharmacists on primary care teams and their impact on the health of patients with Type 2 diabetes.

16 Jun 2015

Pharmaceuticals News and Research

Wilson Therapeutics supports BIG WOW event to increase awareness of Wilson's Disease

Allergan agrees to acquire KYTHERA Biopharmaceuticals for $2.1 billion

RPCI receives NCI grant to continue research program on photodynamic therapy for head and neck cancers

Rapamycin drug reduces obesity, preserves lean body mass in older rats

Iowa's advanced driving simulator to help assess newly developed artificial lens for cataract patients

DCRI announces new study to better understand lipid management

Atopix raises additional development capital to investigate OC459 for treatment of asthma

CytomX closes $70 million Series D financing round

CQDM, OCE grant $1.5M to speed up drug discovery and development in Quebec-Ontario Life Sciences Corridor

Phase I study: Idarucizumab reverses anticoagulant effect of dabigatran in healthy volunteers

Key prostaglandin metabolic enzyme shows promise as drug target for tissue regeneration

Apexigen initiates APX005M Phase 1 clinical trial in adults with solid tumors

Omeros signs exclusive license agreement with Fagron affiliates for commercialization of OMS103

BiondVax invited to present at EDUFULVAC-NIAID workshop on immunoassay standardization for universal flu vaccines

Pulmatrix announces new inhaled anti-infective therapy to treat CF-associated fungal infections

Althea obtains European GMP certificate from HPRA for commercial aseptic filling and testing

Pulmatrix completes previously announced merger and closes $10 million in private placement

Pulmatrix signs ex-U.S. development agreement with Mylan for bronchodilator therapy

West Pharmaceutical Services hosts groundbreaking ceremony for new manufacturing facility in Ireland

Pharmacists play vital role in improving health of patients with Type 2 diabetes

Event guide: 3rd EHS for Biopharma Summit eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring